TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02937012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate 200 mg manufactured in a pill/capsule presentation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Bezafibrate)
Description: Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
Study: NCT02670070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin 50mg, rosuvastatin 20mg
Description: gemigliptin/rosuvastatin 50/20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin 50mg, rosuvastatin 20mg
Description: gemigliptin/rosuvastatin 50/20mg
Study: NCT03310450

Intervention type: OTHER
Intervention: 140kms cycling
Description: Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)

Intervention type: OTHER
Intervention: 140kms cycling
Description: Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)

Intervention type: OTHER
Intervention: 140kms cycling
Description: Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
Study: NCT01892592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Lifestyle
Description: Patients will receive up to 16 phone based coaching sessions
Study: NCT03086395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
Study: NCT03779308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration therapy
Description: The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
Study: NCT01837030

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous sulfate
Description: Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous sulfate
Description: Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period

Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule Endoscopy
Description: GIVEN capsule
Study: NCT00278642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study: NCT03072784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aortic cross clamping
Description: duration of cross clamping, less than 90 minutes, or more than 90 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aortic cross clamping
Description: duration of cross clamping, less than 90 minutes, or more than 90 minutes
Study: NCT02724384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Plasma Delivery System A
Description: Plasma treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Plasma Delivery System A
Description: Plasma treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Plasma Delivery System B
Description: Plasma treatment
Study: NCT00528021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-0582
Description: BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-0582
Description: BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-0582
Description: BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
Study: NCT00507949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Description: Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
Study: NCT03932370

Intervention type: PROCEDURE
Intervention: endoscopic surgery
Description: The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water

Intervention type: PROCEDURE
Intervention: endoscopic surgery
Description: The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water
Study: NCT03995732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-SOD
Description: PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-SOD
Description: PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-SOD
Description: PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Study: NCT03690076

Intervention type: OTHER
Intervention: Endocarditis
Description: Comparison : Endocarditis vs. control

Intervention type: OTHER
Intervention: Endocarditis
Description: Comparison : Endocarditis vs. control

Intervention type: OTHER
Intervention: Obese vs. control
Description: Comparisons : Obese vs. control
Study: NCT03496012

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.
Study: NCT00522054

Intervention type: OTHER
Group type: OTHER
Intervention: Physical exercise
Description: Tai Chi exercise, twice a week during 12 weeks
Study: NCT01944293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
Study: NCT04182633

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: vancomycin, Miralax, intestinal microbiota
Description: vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo vancomycin, Miralax, placebo intestinal microbiota
Description: placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
Study: NCT04673227

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw and the analysis of blood in laboratory

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw and the analysis of blood in laboratory

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood draw and the analysis of blood in laboratory
Study: NCT00316355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CBT
Description: CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care CBT
Description: In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
Study: NCT02861768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharyngeal swab
Study: NCT01855763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study: NCT04072055

Intervention type: DEVICE
Intervention: MOTO Medial
Description: MOTO medial unicompartmental knee system
Study: NCT02414399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: oral administration of Azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 days of taste/appearance/bottle-matched inactive substance
Study: NCT03018587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruSculpt
Description: All subjects will receive 1 truSculpt radiofrequency treatment
Study: NCT03173131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative opioid counseling
Description: Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
Study: NCT03406247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months
Study: NCT03193645

Intervention type: DRUG
Intervention: Degarelix
Description: Injection
Study: NCT04436536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking training with random speed changes
Description: Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking training with blocked speed changes
Description: Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
Study: NCT01876251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 10 mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 50 mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 100 mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Solution for IV infusion 75 mg/m\^2, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Solution for IV infusion 100 mg/m\^2, every 3 weeks
Study: NCT04497129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROMTech PortableConnect
Description: ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation and CPM Device
Description: Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
Study: NCT02220842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
Study: NCT03329222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific hydrolysed proteins
Description: An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cow's milk with prebiotics mixture
Description: Standard cow's milk with prebiotics mixture
Study: NCT02422888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
Study: NCT02214602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
Study: NCT00504907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA9881
Description: Single oral escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02419326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Description: UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
Study: NCT02466867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin® Cream, 2% (younger pediatric cohort)
Description: Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin® Cream, 2% (older pediatric cohort)
Description: Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
Study: NCT01205828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: ABT-888 40 mg BID PO Days 1-7 every 28 days
Study: NCT04316377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: 400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
Study: NCT03059095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga & Meditation
Description: Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
Study: NCT04485143

Intervention type: DEVICE
Intervention: Wisdom bracelet
Description: routine medical
Study: NCT03262454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
Study: NCT02991742

Intervention type: OTHER
Intervention: contrast media
Description: Compare 2 contrast media

Intervention type: OTHER
Intervention: contrast media
Description: Compare 2 contrast media
Study: NCT01950247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectafer
Description: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Study: NCT03277742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community intervention
Description: Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: DOTS plus standard DM2 care
Study: NCT03853811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO)
Description: The intervention group will receive the custom AFO to use in their standard Mitchell shoe.